Effects of thrombopoietin pre-treatment on peri-liver transplantation thrombocytopenia in a mouse model of cirrhosis with hypersplenism

Figure 1 Comparison of routine blood and biochemistry results between the experimental and control groups during the perioperative period of liver transplantation. The experimental group was treated with thrombopoietin, while the control group was treated with an equal amount of saline. ^aP < 0.05; ^bP < 0.01. ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase.

Figure 2 Evaluation of the responsiveness to thrombopoietin pre-treatment and Differences in thrombopoietin and c-Mpl levels. A and B: Evaluation of the responsiveness to thrombopoietin pre-treatment in thrombopoietin receptor-deficient mice and C57B/6J mice during the perioperative period of liver transplantation; C and D: Differences in thrombopoietin and c-Mpl levels between the experimental and control groups during the perioperative period of liver transplantation determined by enzyme-linked immunosorbent assay. The experimental group was treated with thrombopoietin, while the control group was treated with an equal amount of saline. ^aP < 0.05; ^bP < 0.01. TPO: Thrombopoietin.

Figure 3 Comparison of the HE-stained liver tissues between the experimental and control groups after liver transplantation. The experimental group was treated with thrombopoietin, while the control group was treated with an equal amount of saline. The arrows indicate the area of inflammatory necrosis.

Figure 4 Changes in the expression of Jak/STAT pathway proteins in the bone marrow stem cells of C57BL/6J mice and thrombopoietin receptor-deficient mice after thrombopoietin pre-treatment using Western blotting. TPO: Thrombopoietin; STAT: Signal transducers and activators of transcription.